This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Advanced strategies and tools are being implemented to establish the safety and efficacy of new therapeutic modalities, with the development of new biomarkers becoming one of the most relevant approaches for enhancing the precision and utility of early-stage studies.
Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. The company is “preparing for clinicaldevelopment in 2026” across multiple indications, Goutopoulos said. You can unsubscribe at anytime.
This dual role enables him to bridge research and clinical practice, ensuring scientific innovation is directly informed by patient care. “As Protocol development can be a complex and meticulous process,” he explains, “as it’s crucial to ensure that trial candidates meet the necessary inclusion criteria.”
This study explored the effects of beginning treatment with lower starting doses of MariTide to improve tolerability while maintaining clinical benefit. Both data sets now provide foundational insight into the design and direction of Amgen’s upcoming Phase 3 MARITIME clinicaldevelopment program.
Effective financial management is a cornerstone in the success of clinicaltrials, which are integral to the advancement of drug discovery. As the pharmaceutical and biotech industries continue to evolve, clinicaltrials become more complex, and the importance of robust financial oversight has never been clearer.
Clinical genomics, powered by NGS, enables more precise target validation, improved patient stratification and optimised trial design, ultimately aiming to increase PoS. This approach overcomes the limitations of traditional methods that analyse only single modalities of information. Highlighting data integration.
The complexity of diagnosing IPF, understanding its root causes, and translating preclinical findings to clinical success make it a challenging disease for drug development. However, recent advancements and strategic approaches in clinicaltrials offer hope that additional treatments are on the way.
Biopharma and biotech industries are facing remarkable challenges as the cost of developing new drugs has surged dramatically and clinicaltrial timelines have extended significantly. For example, over the past decade, the average time required to complete a clinicaltrial has increased by approximately 20-30%.
The results from the Phase I/II NXTAGE trial, announced during the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C., The trial is evaluating NXT007 in people with hemophilia A without factor VIII inhibitors who have not previously been treated with Hemlibra.
Real-world data (RWD) and real-world evidence (RWE) have emerged as transformational tools in addressing these hurdles, advancing rare disease drug development. Moreover, in some rare disease trials, it is unethical to design a control group of patients with a placebo.
Regulatory Considerations for Oligonucleotide Drug Development and Safety In 2024, the U.S. It also outlines recommendations for drug-drug interaction assessments during clinicaldevelopment, such as the assessment of appropriate biomarkers that reflect modulation of the target protein.
Balancing generative AI opportunities and risks Generative AI offers unparalleled opportunities for transforming various aspects of health care and clinical research. In clinicaltrials, generative AI accelerates trial designs through protocol optimization and enrollment forecasting, leading to faster and more effective studies.
Regulatory bodies such as the FDA oversee clinicaltrials to ensure that studies’ design, conduction, analysis, and reporting are per established guidelines and laws. Any delays or missteps in bioanalysis during a Phase I trial can derail the trajectory of a promising drug.
4 Essential Topics to Cover in Your First CRO Meeting pmjackson Fri, 11/15/2024 - 19:22 Starting a partnership with a contract research organization (CRO) is a sometimes intimidating—yet exciting—first step in your drug development journey. Be prepared to share necessary information about your study with the CRO,” says Chad.
The decision follows an analysis of topline data from a Phase 1b clinical study, which demonstrated encouraging safety and efficacy results in patients with DOK7-CMS, one of the more severe and prevalent subtypes of this ultra-rare neuromuscular disorder. Detailed data from the trial will be shared at an upcoming medical conference.
This natural evolution in regulatory guidance acknowledges that while safety remains paramount, it is equally essential to ensure that therapies are accessible to those in need within the framework of informed medical oversight. This shift may occur through enhanced enrollment by expanding trial accessibility to a broader range of sites.
Rilzabrutinib: A Potentially Transformative Therapy in ITP Among the most anticipated presentations is new data from the LUNA 3 phase 3 clinicaltrial evaluating rilzabrutinib, an investigational, reversible, oral BTK inhibitor, in adults with immune thrombocytopenia (ITP).
This integrated strategy allows BeOne to move seamlessly from early discovery through proof-of-concept to pivotal clinicaltrials, reducing development timelines and enhancing scalability. To date, the company has conducted more than 170 clinicaltrials across 40 countries, enrolling over 25,000 patients.
Developing a new drug takes an average of 10–15 years and costs upwards of $2 billion, yet the majority of drug candidates fail before reaching regulatory approval. The failure rate in clinicaltrials exceeds 90%, often due to insufficient safety data, efficacy concerns, or regulatory non-compliance.
Nonclinical safety assessment serves as a cornerstone in drug development, providing essential data to identify early signs of potential toxicity and inform subsequent clinicaltrial design. CAR T cells) WHAT IS THE BENEFIT OF NONCLINICAL CYTOKINE RELEASE EVALUATION?
Drug-drug interactions (DDI) are a significant concern in clinicaltrials, where the safe and effective administration of drugs to patients is crucial. Challenges in Managing Drug-Drug Interactions in ClinicalDevelopment Predicting and managing DDI in clinicaltrials is one of the most complex challenges in drug development.
Our skepticism was based on our understanding of the biology of those pathways and informed by observations made by the Antonia lab, several Roche groups and others that TGF- expression is sufficient to prevent T cell activation. No chemotherapy regimen is used in the trial. The lead program here was bintrafusp alfa, now terminated.
Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Ibtrozi was approved based on a pair of trials showing response rates of 90% and 85%, respectively, in patients who hadn’t previously received another tyrosine kinase inhibitor.
With facilities in Japan and strategic collaborations abroad, JCR is well-positioned to accelerate clinicaldevelopment and expand access to its treatments across multiple continents. The company actively seeks partnerships with academic institutions, research organizations, and biopharma peers to co-develop transformative therapies.
A final lipophilicity adjustment led to the discovery of CDZ173 (leniolisib), a potent PI3K selective inhibitor with suitable properties and efficacy for clinicaldevelopment as an anti-inflammatory therapeutic. 2] [5] It is a kinase inhibitor [2] [6] that is taken by mouth. [2] mmol) in CH 2 CI 2 (100 mL), was added TFA (41.8
Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. You can unsubscribe at anytime. Until Vykat came along, though, no drug therapies were specifically approved to curb the all-consuming hunger that hallmarks the condition.
This expansion is creating opportunities for clinicaltrials related to a range of new therapy areas and their subpopulations. The SELECT trial set out to understand whether the drug has similar effect on patients without diabetes.
Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Dive Insight: Lexeo is developing treatments for heart conditions, such as cardiomyopathy associated with Friedreich’s ataxia and plakophilin-2 arrhythmia. TechTarget, Inc.s
The draft guidance includes FAQs covering topics from across disciplines: regulatory review; chemistry, manufacturing, and controls (CMC); nonclinical and pharmacology/toxicology (PT); clinical; and clinical pharmacology. Section #3: Human Trials Finally, the guidance provides a quick overview of clinical study recommendations.
It typically begins with the filing of a patent application and extends through various stages: Discovery and initial patent filing Clinicaltrials and regulatory approval Market exclusivity period Patent expiration and generic competition Understanding this lifecycle is crucial for developing a strategy that maximizes protection at every stage.
Food and Drug Administration (FDA) within 30 days, providing a structured timeline for progressing with clinicaltrials. Early engagement with the FDA can help set expectations for future regulatory steps and ensure that non-clinical and clinicaltrial data meet global regulatory requirements.
Real-world data paired with machine learning is a game changer in drug development RWD is becoming increasingly important in influencing the drug development landscape, particularly when used to develop the natural history and patient journey through disease.
Selecting the right CRO to partner with on your development program is a pivotal decision that can shape the trajectory of your product’s development. Our consultative approach ensures success by integrating research methodology, regulatory affairs strategy, and clinical operations. You can expect transparency.
As clinicaldevelopment of an investigational product proceeds, Sponsors often conduct global clinicaltrials which require preparation of content to support dossiers in multiple geographies, meeting the regulatory requirements of each region.
Patients are the backbone of clinicaltrials, playing an essential role in the drug development process. This engagement is often less understood and is underutilized by sponsors, meaning a significant element of the trial and drug experience is missed during sponsor engagement with the FDA.
Written by Natalia Muehlemann, Vice President, ClinicalDevelopment, and Ari Brettman, Senior Managing Director, Blackstone Life Sciences When working with investors, it’s critical that drug and device developers consider how their clinicaltrial design aligns with investment priorities.
Clissold — The trio of CDER, CBER, and CDRH released a new draft guidance titled “ Use of Data Monitoring Committees in ClinicalTrials ” that revises the 2006 guidance “Establishment and Operation of ClinicalTrial Data Monitoring Committees” and, when final, will replace the 2006 guidance.
The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021. AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinicaldevelopment of ATX01. More information at www.algotx.com. View source version on businesswire.com: [link].
To keep a pulse on this rapidly changing industry, the PPD clinical research business of Thermo Fisher Scientific surveyed 150 leaders in the biopharma and biotech industries for the second consecutive year. Differences in size, resources and agility have led the two groups to take different approaches to clinicaldevelopment.
Written By: Derek Ansel, MS, CCRA, Executive Director, Therapeutic Strategy Lead, Rare Disease Given that 80% of rare diseases have a genetic etiology, genetic implications should be addressed at the onset of a clinical program to support trial enrollment. One diagnostic example that I discussed in my presentation is autism.
The update includes an addition to the Indications and Usage section of the label (Section 1) to emphasize the disease stages studied in the clinicaltrials, as seen below ( italics to note updated language). Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).
Despite accumulating learnings from early phases, several uncertainties remain to be addressed when designing pivotal trials. Adaptive trials can help mitigate uncertainties; however, the trade-offs and their impact differ in the confirmatory setting. Quantitative strategies can help inform decisions and optimize choices.
This process can be daunting, but understanding how to manage feedback effectively is crucial for developing and ultimately gaining approval for new therapies, especially in oncology clinicaltrials. Our experts can help you navigate early and continual engagement opportunities to receive optimal regulatory feedback.
The possibility for change needs to be ethically sound and clear to all involved, including investigators, site staff and cross-functional team members, like clinical monitors, statisticians, data managers and vendors. Each step of the process is conducted with an eye toward supporting later-phase programs and regulatory submissions.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content